SLC26A4 mutations can cause a distinctive hearing loss phenotype with sudden drops and fluctuation in patients. Existing Slc26a4 mutant mouse lines have a profound loss of hearing and vestibular function, with severe inner ear malformations that do not model this human phenotype. In this study, we generated Slc26a4-insufficient mice by manipulation of doxycycline administration to a transgenic mouse line in which all Slc26a4 expression was under the control of doxycycline. Doxycycline was administered from conception to embryonic day 17.5, and then it was discontinued. Auditory brainstem response thresholds showed significant fluctuation of hearing loss from 1 through 3 months of age. The endocochlear potential, which is required for inner ear sensory cell function, correlated with auditory brainstem response thresholds. We observed degeneration of stria vascularis intermediate cells, the cells that generate the endocochlear potential, but no other abnormalities within the cochlea. We conclude that fluctuations of hearing result from fluctuations of the endocochlear potential and stria vascularis dysfunction in Slc26a4-insufficient mouse ears. This model can now be used to test potential interventions to reduce or prevent sudden hearing loss or fluctuation in human patients. Our strategy to generate a hypomorphic mouse model utilizing the tet-on system will be applicable to other diseases in which a hypomorphic allele is needed to model the human phenotype.
Introduction
SLC26A4 encodes an 86-kDa transmembrane anion exchanger called pendrin. Mouse Slc26a4 is expressed in the inner ear, thyroid, kidney, lung, and several other organs (Alesutan et al., 2011; Everett et al., 1997; Rehman et al., 2014) . Pendrin mediates Cl − /HCO 3 − exchange in the developing inner ear and is required for proper endolymphatic pH and volume (Choi et al., 2011; Wangemann et al., 2007) . SLC26A4 mutations cause Pendred syndrome (PS), an autosomal recessive disorder comprised of goiter, hearing loss (Pendred, 1896) and enlargement of vestibular aqueduct (EVA) (Reardon et al., 2000) . EVA is a common inner ear malformation detected in up to 20% of children with sensorineural hearing loss (Morton and Nance, 2006). However, many cases of EVA are not associated with thyroid goiter (PS) or SLC26A4 mutations.
Patients with EVA can have hearing loss whose onset is postlingual with severity that ranges from mild to profound with variable audiometric configurations (King et al., 2010) . Progressive or fluctuating hearing loss is commonly observed and may be precipitated by minor head injury or barotrauma in some patients (Griffith and Wangemann, 2011) . Although some studies identify associations of inner ear morphology with hearing levels or prognosis (Campbell et al., 2011; Dahlen et al., 1997) , the associations may be epiphenomenal reflections of underlying correlations with age, genotype or other factors. When underlying genotypic and phenotypic correlations are accounted for, we could not detect an association of the presence of a cochlear anomaly with severity of hearing loss in ears with EVA (King et al., 2010) . Moreover, most studies have found no correlation of the size of the vestibular aqueduct with degree of hearing loss in ears meeting the diagnostic criteria for EVA originally proposed by Valvassori and Clemis (Griffith et al., 1996; King et al., 2010) . Therefore gross morphogenetic anomalies seem unlikely to be the direct cause of hearing loss in EVA. Neurobiology of Disease 66 (2014) 53-65 
